Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Fondell E, Lagerros YT, Sundberg CJ, Lekander M, Balter O, Rothman KJ, Balter K. Physical activity, stress, and self-reported upper respiratory tract infection. Med Sci Sports Exerc. 2011 Feb 1;43(2):272-9.